Lovotibeglogene Autotemcel

Summary

Lovotibeglogene Autotemcel (CHEMBL4650269) is an approved gene; indicated across 1 condition including sickle cell disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650269
Name	Lovotibeglogene Autotemcel
Type	Gene
Max phase	4

Also known as: BB-1111, Lovotibeglogene autotemcel, Lyfgenia, bb1111, LOVOTIBEGLOGENE AUTOTEMCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sickle cell disease	4	MONDO:0011382	MONDO:0011382

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04293185	PHASE3	ACTIVE_NOT_RECRUITING	A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).